J. Thomas

发表

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.

M. Piccart, R. Paridaens, J. Schornagel, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).

D. Lacombe, J. Bogaerts, J. Bernier, 2008, European journal of cancer.

Diagnosis of Malignant Melanoma with Radiolabeled Monoclonal Antibodies: Current Status

W. Robinson, J. Thomas, G. Friefeld, 1986, Drug intelligence & clinical pharmacy.

A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.

A. Hagenbeek, M. Henry-Amar, B. D. de Pauw, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of erlotinib (OSI-774) in patients with hepatocellular or biliary cancer.

P. Philip, M. Mahoney, R. Donehower, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.

A. Hagenbeek, E. Noordijk, L. Bijnens, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

G. Brittinger, D. Huhn, U. Jaeger, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer.

M. Glabbeke, H. Kluin-Nelemans, M. Henry-Amar, 2002, European journal of cancer.

Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group.

M. van Glabbeke, C. de Wolf‐Peeters, B. D. de Pauw, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin's lymphomas.

J. Raemaekers, E. Noordijk, R. V. D. van der Maazen, 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Management of relapse and survival in advanced stage Hodgkin's disease: the EORTC experience.

A. Hagenbeek, M. Henry-Amar, B. D. de Pauw, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

77 Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I–II Hodgkin's disease six-year results of the EORTC-GPMC controlled clinical trials ‘H7-VF’, ‘H7-F’ and ‘H7-U’

A. Hagenbeek, E. Noordijk, U. Tirelli, 1997 .

Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial.

A. Hagenbeek, R. Bouabdallah, F. Morschhauser, 2005 .

EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma.

C. de Wolf‐Peeters, U. Tirelli, A. Delmer, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Cu

J. Raemaekers, A. Hagenbeek, E. Noordijk, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.

A. Eggermont, V. Cocquyt, P. Patel, 2011, European journal of cancer.

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

P. Dupont, L. Mortelmans, G. Verhoef, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie.

U. Tirelli, E. Noordijk, A. Mandard, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.

A. Hagenbeek, E. Noordijk, J. H. Meerwaldt, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group.

M Tubiana, E. Noordijk, M. Tubiana, 1992, European journal of cancer.

Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group.

E. Noordijk, J. Cosset, M. Henry-Amar, 1990, International journal of radiation oncology, biology, physics.

Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.

M Tubiana, A Tanguy, E. Noordijk, 1989, Blood.

Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation.

A. Hagenbeek, S. Pittaluga, C. de Wolf‐Peeters, 1996, Blood.

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.

H. Kluin-Nelemans, V. Zagonel, A. Carbone, 2001, Journal of the National Cancer Institute.

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.

A. Eggermont, C. Punt, P. Patel, 2006, European journal of cancer.

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.

M Van Glabbeke, M. van Glabbeke, E. Noordijk, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.

A. Hagenbeek, M. van Glabbeke, M. Glabbeke, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential Use of lndium-111 Labeled Monoclonal Antibodies 96.5 and ZME-018 does not Increase Detection Sensitivity for Metastatic Melanoma

J. Murray, P. Bunn, M. Rosenblum, 1989, Clinical nuclear medicine.

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

P. Dupont, L. Mortelmans, G. Bormans, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-Hodgkin's lymphomas in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group Study.

D. Serraino, V. Zagonel, U. Tirelli, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols.

E. Noordijk, J. Bosq, M. Henry-Amar, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Involved-field radiotherapy in patients with stage III/IV Hodgkin’s lymphoma: first results of the randomised EORTC trial # 20884

J. Raemaekers, U. Tirelli, M. Henry-Amar, 2001 .

Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study.

J. Raemaekers, B. Coiffier, A. Allgeier, 2014, Human reproduction.

First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL)

E. Noordijk, M. Henry-Amar, F. Morschhauser, 2005 .

Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern.

M. Glabbeke, C. de Wolf‐Peeters, N. Duez, 1991, International journal of radiation oncology, biology, physics.